I.Z. GAYDUKOVA, A.P. REBROV, O.A. LEBEDINSKAYA, A.I. AKULOVA, A.V. APARKINA

Saratov State Medical University named after V.I. Razumovskiy, 112 B. Kazachya St., Saratov, Russian Federation, 410012

Gaydukova I.Z. — Cand. Med. Sc., PhD student of the Department of Hospital Therapy of Faculty of general medicine, tel. +7-903-329-03-59, e-mail: ubp1976@list.ru

Rebrov A.P. — D. Med. Sc., Professor, Head of the Department of Hospital Therapy of Faculty of general medicine, tel. (8452) 49-14-37, e-mail: andreyrebrov@yandex.ru

Lebedinskaya O.A. — postgraduate student of the Department of Hospital Therapy of Faculty of general medicine, tel. (8452) 49-14-37, e-mail: lebedcard@yandex.ru

Aparkina A.V. — postgraduate student of the Department of Hospital Therapy of Faculty of general medicine, tel. (8452) 49-14-37, e-mail: alena437539@yandex.ru

Akulova A.I. — postgraduate student of the Department of Hospital Therapy of Faculty of general medicine, tel. (8452) 49-14-37, e-mail: ann-nov@yandex.ru

During the 4-year study of 446 patients with axial spondyloarthritis (ankylosing spondylitis, psoriatic arthritis and axial spondyloarthritis in the presence of psoriasis), who at the beginning of the study had no clinical signs of heart disease, and of healthy individuals, there was studied the dynamics of cardiovascular diseases during spondylitis. There was found that at comparable factors of cardiovascular risk of coronary artery disease, atrial fibrillation and diabetes in patients with psoriatic arthritis occur more frequently than in patients with ankylosing spondylitis and without spondyloarthritis. For the first time it was shown that cardiovascular morbidity in patients with axial lesions of the musculoskeletal system and psoriasis are comparable to patients with psoriatic arthritis.

Key words: spondylitis, ankylosing spondylitis, psoriatic arthritis, cardiovascular disease, cardiovascular mortality.

REFERENCES

1. Schoels M.M., Braun J., Dougados M. et al. Treating axial and peripheral spondyloarthritis, including psoriatic arthritis, to target: results of a systematic literature search to support an international treat-to-target recommendation in spondyloarthritis. Ann Rheum Dis., 2014, vol. 73(1), pp. 238-242.
2. Han C., Robinson D.W., Hackett M.V. et al. Cardiovascular disease and risk factors in patients with rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis. J Rheumatol., 2010, vol. 33, 11, pp. 2167-2172.
3. Peters M.J., Symmons D.P., McCarey D. et al. EULAR evidence-based recommendations for cardiovascular risk management in patients with rheumatoid arthritis and other forms of inflammatory arthritis. Ann Rheum Dis., 2010, vol. 69, 2, rr. 325-331.
4. van Halm V.P., Peters M.J., Voskuyl A.E. et al. Rheumatoid arthritis versus diabetes as a risk factor for cardiovascular disease: a cross-sectional study, the CARRE Investigation. Ann Rheum Dis, 2009, vol. 68, pp. 1395-400.
5. Johnsson H., McInnes I.B., Sattar N. et al. Cardiovascular and metabolic risks in psoriasis and psoriatic arthritis: pragmatic clinical management based on available evidence. Ann Rheum Dis, 2012, vol. 71, pp. 480-483.
6. Horreau C., Pouplard C., Brenaut E. et al. Cardiovascular morbidity and mortality in psoriasis and psoriatic arthritis: a systematic literature review. JEADV, 2013, vol. 27(3), pp. 12-29.
7. Gunnstein Bakland, Jan Tore Gran, Johannes C Nossent. Increased mortality in ankylosing spondylitis is related to disease activity. Ann Rheum Dis, 2011, vol. 70, pp. 1921-1925.
8. Mathieu S., Gossec L., Dougados M. et al. Cardiovascular profile in ankylosing spondylitis: a systematic review and meta-analysis. Arthritis Care Res (Hoboken), 2011, vol. 63(4), pp. 557-563.
9. Ya-Ping Huang, Yen-Ho Wang, Shin-Liang Pan. Increased Risk of Ischemic Heart Disease in Young Patients with Newly Diagnosed Ankylosing Spondylitis – A Population-Based Longitudinal Follow-Up Study. PLOS ONE, 2013, vol. 8(5), pp. e5-e64.
10. Buckley C., Cavill C., Taylor G. et al. Mortality in psoriatic arthritis – a single-center study from the UK. J Rheumatol, 2010, vol. 37, pp. 2141-2144.
11. Wong K., Gladman D.D., Husted J. et al. Mortality studies in psoriatic arthritis: results from a single outpatient clinic. I. Causes and risk of death. Arthritis Rheum, 1997, vol. 40, pp. 1868-1872.
12. Gaydukova I.Z., Rebrov A.P. Features of clinical research in inflammatory joint diseases. Dnevnik kazanskoy meditsinskoy shkoly, 2013, no. 2 (2), pp. 91-95 (in Russ.).
13. Rebrov A.P., Gaydukova I.Z. Damage to the endothelium and vascular wall stiffness in patients with psoriatic arthritis. Saratovskiy nauchno-meditsinskiy zhurnal, 2009, no. 5 (4), pp. 544-548 (in Russ.).
14. Rebrov A.P., Gaydukova I.Z., Poddubnyy D.A. Cardiovascular disease in patients with ankylosing spondylitis. Nauchno-prakticheskaya revmatologiya, 2012, no. 2, pp. 100-105 (in Russ.).
15. Gelfand J.M., Troxel A.B., Lewis J.D. et al. The risk of mortality in patients with psoriasis: results from a population-based study. Arch Dermatol, 2007, vol. 143, rr. 1493-1499.
16. Gladman D.D., Ang M., Su L., Tom B.D. et al. Cardiovascular morbidity in psoriatic arthritis. Ann Rheum Dis, 2010, vol. 68(7), rr. 1131-1135.
17. Gladman D.D., Farewell V.T., Wong K., Husted J. Mortality studies in psoriatic arthritis: results from a single outpatient center. II. Prognostic indicators for death. Arthritis Rheum, vol. 41(6), pp. 1103-1110.
18. Jamnitski A., Visman I.M., Peters M.J. et al. Prevalence of cardiovascular diseases in psoriatic arthritis resembles that of rheumatoid arthritis. Ann Rheum Dis, 2010, vol. 1(70), pp. 284-288.
19. Shelagh M. Szabo, Adrian R. Levy et al. Increased Risk of Cardiovascular and Cerebrovascular Diseases in Individuals With Ankylosing Spondylitis A Population-Based Study. Arth & Rheum, 2011, vol. 63(11), pp. 3294-3304.
20. Wilson F.C., Icen M., Crowson C.S. et al. Incidence and clinical predictors of psoriatic arthritis in patients with psoriasis: A population-based study. Arthritis Rheum, vol. 61(2), rr. 233-239.
21. Anna Jamnitski, Deborah Symmons, Mike J.L. Peters et al. Cardiovascular comorbidities in patients with psoriatic arthritis: a systematic review. Clinics, 2013, vol. 68(3), pp. 305-309.
22. Ahlehoff O., Gislason G.H., Charlot M. et al. Psoriasis is associated with clinically significant cardiovascular risk: a Danish nationwide cohort study. J Intern Med, 2011, vol. 270, pp. 147-157.
23. Taylor W., Gladman D., Helliwell P. et al. Classification criteria for psoriatic arthritis: development of new criteria from a large international study. Arthritis Rheum, 2006, vol. 54(8), pp. 2665-2673.
24. van der Linden S., Valkenburg H.A., Cats A. Evaluation of diagnostic criteria for ankylosing spondylitis. A proposal for modification of the New York criteria. Arthritis Rheum, 1984, vol. 27(4), pp. 361-368.
25. Korotaeva T.V. Psoriaticheskiy artrit: klinika, diagnostika, patogenez, lechenie, markery kardiovaskulyarnogo riska, pod redaktsiey E.L. Nasonova [Psoriatic arthritis: clinical features, diagnosis, pathogenesis, treatment, markers of cardiovascular risk. Ed. by E.L. Nasonov]. Moscow, 2013. P. 309.
26. Gelfand J.M., Neimann A.L., Shin D.B. et al. Risk of myocardial infarction in patients with psoriasis. JAMA, 2006, vol. 296, rr. 1735-1741.
27. Gottlieb A.B., Chao C., Dann F. Psoriasis comorbidities. J Dermatolog Treat, 2008, vol. 19, pp. 5-21.
28. Goff D.C.Jr., Lloyd-Jones D.M., Bennett G. et al. 2013 ACC/AHA guideline on the assessment of cardiovascular risk: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. Circulation, 2014, vol. 24, suppl 2, pp. 49-73.
29. Rebrova O.Yu. Statisticheskiy analiz meditsinskikh dannykh. Primenenie paketa prikladnykh programm STATISTICA [Statistical analysis of medical data. The use of the application package STATISTICA]. Moscow: Media-Sfera, 2002.
30. Eder L., Chandran V., Gladman D.D. The Framingham Risk Score underestimates the extent of subclinical atherosclerosis in patients with psoriatic disease. Ann Rheum Dis, 2013, vol. 10, pp. 1-7.
31. Lihi Eder, Arane Thavaneswaran, Vinod Chandran et al. Increased burden of inflammation over time is associated with the extent of atherosclerotic plaques in patients with psoriatic arthritis. Ann Rheum Dis, 2014, vol. 10, pp. 1-6.
32. Favarato M.H., Mease P., Gonçalves C.R. et al. Hypertension and diabetes significantly enhance the risk of cardiovascular disease in patients with psoriatic arthritis. Clin Exp Rheumatol, 2014, vol. 32(2), rr. 182-187.
33. Shawn Rose, Jenny Dave, Corina Millo et al. Psoriatic arthritis and sacroiliitis are associated with increased vascular inflammation by 18-fluorodeoxyglucose positron emission tomography computed tomography: baseline report from the Psoriasis Atherosclerosis and Cardiometabolic Disease Initiative. Arthritis Research & Therapy, 2014, vol. 16, r. 161, pp. 2-9.
34. Deepak Jadon William Tillett Dinny Wallis, Charlotte Cavill, John Bowes. et al. Exploring ankylosing spondylitis-associated ERAP1, IL23R and IL12B gene polymorphisms in subphenotypes of psoriatic arthritis. Rheumatology, 2013, vol. 52, pp. 261-266.
35. Eirís N., González-Lara L., Santos-Juanes J. et al. Genetic variation at IL12B, IL23R and IL23A is associated with psoriasis severity, psoriatic arthritis and type 2 diabetes mellitus. J Dermatol Sci, 2014, vol. 75(3), pp. 167-172.